Compare Citius Pharmaceuticals Inc (CTXR) vs Nucor Corporation (NUE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Nucor Corporation — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Nucor Corporation trades at $250.33 (market cap $55.84B). The key difference: Nucor Corporation is far larger — about 4099.9× Citius Pharmaceuticals Inc's market cap, and Nucor Corporation pays a 0.91% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Nucor Corporation for 78 Days on average.
| CTXR | NUE | |
|---|---|---|
Market Cap | $13.62M | $55.84B |
Volume | 132,438 | 848,835 |
Sector | Health | Basic Materials |
52-Week High | $1.82 | $274.74 |
52-Week Low | $0.48 | $131.78 |
Typical Hold Time | 17 Days | 78 Days |
Enterprise Value | $3.79M | $60.25B |
Dividend Yield | — | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4994, down 1.73% with a bearish technical signal despite oscillators showing oversold conditions. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR commercial sales, but continues to post significant losses with a -651.27% net income margin. Recent news highlights strong commercial momentum for LYMPHIR with 44 institutions ordering the treatment since launch.
The stock presents a high-risk opportunity with analyst consensus strongly bullish (83% buy ratings, $5 price target) but fundamental challenges persist. Key risks include ongoing cash burn and execution of commercial strategy, while potential upside depends on successful LYMPHIR adoption and path to profitability.
Nucor (NUE) trades at $246.14, down 0.12% on the day, with a bearish technical signal despite recent earnings beats. The stock shows mixed sentiment with a moderate buy analyst consensus and a $266.88 price target. Revenue rebounded to $32.49B in 2025, though net margins have compressed from 2022 peaks. Recent news highlights steel sector volatility and Nucor's Q3 2026 guidance projecting higher earnings on improved pricing.
Outlook remains cautiously optimistic with earnings growth potential from steel price strength and operational efficiency, balanced by competitive pressures from new capacity and cyclical demand risks. The stock offers value at a P/E of 19.64 and a solid dividend history, but investors face headwinds from margin pressure and industry competition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →
